Skip to main navigation Skip to search Skip to main content

Concurrent nonavalent human papillomavirus (HPV) vaccination and immune stimulation with imiquimod to treat recalcitrant HPV-associated high grade vaginal intra-epithelial neoplasia

  • R. Farrell
  • , J. Zaunders
  • , I. M. Poynten
  • , L. Anderson
  • , L. Evans
  • Chris O'Brien Lifehouse
  • The University of Sydney
  • St. Vincent's Hospital Sydney
  • University of New South Wales
  • Royal Prince Alfred Hospital
  • Liverpool Hospital

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
31 Downloads (Pure)

Abstract

This is the first report describing detailed T cell responses to viral-like proteins contained in an HPV specific vaccine given in combination with Imiquimod for treatment of persistent VAIN2/3. We postulate that stimulation of the innate immune system with Imiquimod and the specific CD4 and CD8T cell responses following HPV vaccination with Gardasil9@ combined to induce clinical remission in a woman with treatment-refractory disease.
Original languageEnglish
Article number101350
Number of pages6
JournalGynecologic Oncology Reports
Volume52
DOIs
Publication statusPublished - Apr 2024
Externally publishedYes

Keywords

  • HPV vaccine
  • Human papillomavirus (HPV)
  • Imiquimod
  • Vaginal intraepitheial neoplasia (VAIN)

Fingerprint

Dive into the research topics of 'Concurrent nonavalent human papillomavirus (HPV) vaccination and immune stimulation with imiquimod to treat recalcitrant HPV-associated high grade vaginal intra-epithelial neoplasia'. Together they form a unique fingerprint.

Cite this